logo

Regenxbio Inc (RGNX)



Trade RGNX now with
  Date
  Headline
8/8/2018 7:38:42 AM REGENXBIO Q2 Revenues $40.0 Mln Vs. $6.6 Mln Prior Year
5/29/2018 4:11:14 PM REGENXBIO Appoints Alexandra Glucksmann To Board Of Directors
5/2/2018 7:08:59 AM REGENXBIO Receives FDA Fast Track Designation For RGX-121 Gene Therapy For Mucopolysaccharidosis Type II
1/8/2018 8:36:52 AM AveXis Acquires Exclusive Rights To Entire NAV Technology Platform For Development Of Treatments For SMA
1/8/2018 8:26:32 AM AveXis Acquires Exclusive Rights To Entire NAV Technology Platform For The Development Of Treatments For SMA
12/19/2017 7:06:41 AM REGENXBIO Announces IND Active For Phase I/II Trial Of RGX-121 To Treat Mucopolysaccharidosis Type II
10/3/2017 8:33:05 AM Ultragenyx Enters Into Definitive Agreement To Acquire Dimension For $6/Shr Cash
10/2/2017 8:12:58 AM Dimension Board Determines Ultragenyx’s Proposal To Buy Dimension For $6.00/shr Constitutes Superior Proposal
9/20/2017 7:04:07 AM REGENXBIO Announces Completion Of Dosing Of First Cohort In Phase I Clinical Trial Of RGX-314 Gene Therapy For Wet AMD